Chemotherapy Breakthrough for Young Hodgkin's Patients

Good news for patients diagnosed with Hodgkin's lymphoma (HL) who are under 22 years of age.

Research published online in the journal Blood suggests that so-called dose-dense drug delivery is more effective and presents the young HL patients with fewer long-term risks to their health than traditional chemotherapy regimens,

The new regimen, idenitifed by researchers at Hasbro Children's Hospital, in Providence, Rhode Island, combines 6 chemo drugs into a single dose-dense regimen, one that limits the cumulative amount of each chemo drug, below the recognised thresholds known for causing long-term toxicity.

What are the more traditional chemotherapy regimens for Hodgkin's?


And …


What is the new regimen?


What did researchers hope to achieve with this new regimen?

--Cure the patient's Hodgkin's disease
--Reduce the toxicity of chemotherapy for these patients (thereby reducing infertility, second malignancy, and cardiopulmonary toxicity) while still ensuring its efficacy;
--Reach a rapid early response (RER) in order to further reduce cumulative therapy;
--Increase event-free survival;
--Shorten chemotherapy regimens (many patients required only 9 weeks of chemotherapy)

What are the conclusions of the study?

"In essence, we've been able to cure the cancer while reducing the risk of long-term effects on our patients," said Dr. Cindy Schwartz, author of the study. "This study has shown conclusively that the new chemotherapeutic treatment of ABVE-PC simultaneously provides high efficacy and reduces the cumulative doses of chemotherapy and radiation.

"We believe this represents a significant advance in the treatment of HL."

Read more about this breakthrough HERE

More Articles

More Articles is pleased to have the Lymphoma Information Network in the family of associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...